InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025

InMode reported Q2 2026 GAAP revenue of $95.6M, flat YoY, while GAAP operating income fell to $12.3M (from $22.9M), driving GAAP EPS down to $0.29 (vs. $0.42). Consumables and service revenue rose 13% YoY to $22.3M, but gross margin and operating margin both declined (gross margin 75% vs 80%; operating margin 13% vs 24%) on higher COGS, mix, restructuring costs, and added marketing/S&A. The company completed a $87.8M share repurchase (6.38M shares) and guided FY2026 revenues of $365M–$375M with non-GAAP EPS of $1.29–$1.34, while noting margins headwinds are expected to persist and Israel-related regional conflict remains a risk.

Analysis

The key signal is not flat top-line, but the deterioration in operating leverage while the company is still buying back stock. That combination usually marks a late-cycle defense phase: management is protecting share count and headline EPS, but the underlying engine is absorbing more marketing and overhead to defend install base, which tends to force estimate cuts before the market fully prices the slowdown.

The second-order read-through is competitive: recurring revenue is growing faster than capital equipment, which means the economics are shifting toward the installed base. That is good for larger, better-capitalized med-aesthetic platforms that can monetize consumables and service, but it also means smaller capital-equipment peers with weaker installed bases may see channel pressure as customers defer new systems and spend more on utilization of existing fleets. In the near term, this is a multiple story more than an earnings story: a premium device name with stagnant revenue and compressing margins usually rerates toward cash-yielding industrial software-like valuations, not growth med-tech multiples.

The contrarian risk is that the market may be over-discounting a trough: if the restructuring is genuinely behind them, Asia strength and recurring mix can support a 1-2 quarter stabilization window. However, the burden of proof is high because management is explicitly signaling that margin pressure persists, and the absence of a call/roadshow during a special committee process reduces transparency. The stock likely needs either a margin inflection or a strategic event to break the current downtrend; otherwise, buybacks alone are just slowing the drift, not changing the terminal value.

Key Decisions for Investors

• Short INMD on strength over the next 2-6 weeks; use a 3-6 month put spread rather than outright puts to respect buyback support and possible M&A optionality. Target is a rerating toward low-growth device multiples if margins keep compressing.
• If already short, cover only if next quarter shows sequential revenue acceleration and gross margin recovery; otherwise stay with the trade through the next guidance update because margin pressure is the real catalyst, not the revenue print.
• Pair idea: short INMD vs long a higher-quality med-tech compounder such as ISRG over 3-12 months. The spread captures the market’s willingness to pay for durable operating leverage and avoids taking pure sector beta.
• Watch for a strategic bid or go-shop update from the special committee; that is the main reason not to press an oversized bearish position. Any credible transaction process would likely cap downside quickly.
• Set an alert on recurring revenue mix and gross margin: if consumables/service approaches the high-20s as a share of sales without further cost inflation, the bearish thesis weakens materially.